المؤلفون: Ooi J.D., Eggenhuizen P.J., Ng B.H.

مصطلحات الفهرس: Crohn disease/th [Therapy], dendritic cell, DNA immunization, DNA vector, drug targeting, effector cell, fecal microbiota transplantation, graft rejection, immunological tolerance, insulin dependent diabetes mellitus/dt [Drug Therapy], insulin dependent diabetes mellitus/et [Etiology], low drug dose, microbiome, multiple sclerosis/et [Etiology], nonhuman, pemphigus/th [Therapy], phenotype, regulatory T lymphocyte, review, skin lupus erythematosus/th [Therapy], synergistic effect, systemic lupus erythematosus/et [Etiology], T lymphocyte subpopulation, transient expression, treatment outcome, umbilical cord blood, aldesleukin/dt [Drug Therapy], autoantigen, bacterial polysaccharide, beta glucan, butyric acid, CD135 antigen, chimeric antigen receptor/ec [Endogenous Compound], corticosteroid/dt [Drug Therapy], cytokine receptor agonist/dt [Drug Therapy], cytokine receptor agonist/pd [Pharmacology], cytotoxic T lymphocyte antigen 4/ec [Endogenous Compound], Flt3 ligand/cb [Drug Combination], Flt3 ligand/it [Drug Interaction], Flt3 ligand/dt [Drug Therapy], galactan, immunosuppressive agent/dt [Drug Therapy], insulin/dt [Drug Therapy], interleukin 10/dt [Drug Therapy], interleukin 10/pd [Pharmacology], major histocompatibility antigen/ec [Endogenous Compound], mammalian target of rapamycin/ec [Endogenous Compound], mammalian target of rapamycin inhibitor/dt [Drug Therapy], mammalian target of rapamycin inhibitor/pd [Pharmacology], methylprednisolone/do [Drug Dose], methylprednisolone/dt [Drug Therapy], mycophenolic acid/do [Drug Dose], mycophenolic acid/dt [Drug Therapy], nanoparticle, peptide/dt [Drug Therapy], rapamycin/cb [Drug Combination], rapamycin/it [Drug Interaction], rapamycin/dt [Drug Therapy], rapamycin/pd [Pharmacology], recombinant interleukin 2/do [Drug Dose], recombinant interleukin 2/dt [Drug Therapy], short chain fatty acid, T lymphocyte receptor/ec [Endogenous Compound], tacrolimus/do [Drug Dose], tacrolimus/dt [Drug Therapy], transcription factor FOXP3/ec [Endogenous Compound], tumor necrosis factor receptor 2/ec [Endogenous Compound], unclassified drug, tumor necrosis factor receptor 2 agonist/dt [Drug Therapy], tumor necrosis factor receptor 2 agonist/pd [Pharmacology], human, adverse event, antigen specificity, antiinflammatory activity, autoimmune disease/dt [Drug Therapy], autoimmune disease/et [Etiology], autoimmune disease/pc [Prevention], autoimmune disease/th [Therapy], autoimmune hepatitis/th [Therapy], autoimmunity, Bifidobacterium bifidum, biological therapy, CD4+ T lymphocyte, cell therapy, chimeric antigen receptor immunotherapy, chronic inflammation, Review

URL: International Journal of Molecular Sciences
Click here for full text options
LibKey Link

المؤلفون: Ooi J.D., Eggenhuizen P.J., Ng B.H.

مصطلحات الفهرس: Crohn disease/th [Therapy], dendritic cell, DNA immunization, DNA vector, drug targeting, effector cell, fecal microbiota transplantation, graft rejection, immunological tolerance, insulin dependent diabetes mellitus/dt [Drug Therapy], insulin dependent diabetes mellitus/et [Etiology], low drug dose, microbiome, multiple sclerosis/et [Etiology], nonhuman, pemphigus/th [Therapy], phenotype, regulatory T lymphocyte, review, skin lupus erythematosus/th [Therapy], synergistic effect, systemic lupus erythematosus/et [Etiology], T lymphocyte subpopulation, transient expression, treatment outcome, umbilical cord blood, aldesleukin/dt [Drug Therapy], autoantigen, bacterial polysaccharide, beta glucan, butyric acid, CD135 antigen, chimeric antigen receptor/ec [Endogenous Compound], corticosteroid/dt [Drug Therapy], cytokine receptor agonist/dt [Drug Therapy], cytokine receptor agonist/pd [Pharmacology], cytotoxic T lymphocyte antigen 4/ec [Endogenous Compound], Flt3 ligand/cb [Drug Combination], Flt3 ligand/it [Drug Interaction], Flt3 ligand/dt [Drug Therapy], galactan, immunosuppressive agent/dt [Drug Therapy], insulin/dt [Drug Therapy], interleukin 10/dt [Drug Therapy], interleukin 10/pd [Pharmacology], major histocompatibility antigen/ec [Endogenous Compound], mammalian target of rapamycin/ec [Endogenous Compound], mammalian target of rapamycin inhibitor/dt [Drug Therapy], mammalian target of rapamycin inhibitor/pd [Pharmacology], methylprednisolone/do [Drug Dose], methylprednisolone/dt [Drug Therapy], mycophenolic acid/do [Drug Dose], mycophenolic acid/dt [Drug Therapy], nanoparticle, peptide/dt [Drug Therapy], rapamycin/cb [Drug Combination], rapamycin/it [Drug Interaction], rapamycin/dt [Drug Therapy], rapamycin/pd [Pharmacology], recombinant interleukin 2/do [Drug Dose], recombinant interleukin 2/dt [Drug Therapy], short chain fatty acid, T lymphocyte receptor/ec [Endogenous Compound], tacrolimus/do [Drug Dose], tacrolimus/dt [Drug Therapy], transcription factor FOXP3/ec [Endogenous Compound], tumor necrosis factor receptor 2/ec [Endogenous Compound], unclassified drug, tumor necrosis factor receptor 2 agonist/dt [Drug Therapy], tumor necrosis factor receptor 2 agonist/pd [Pharmacology], human, adverse event, antigen specificity, antiinflammatory activity, autoimmune disease/dt [Drug Therapy], autoimmune disease/et [Etiology], autoimmune disease/pc [Prevention], autoimmune disease/th [Therapy], autoimmune hepatitis/th [Therapy], autoimmunity, Bifidobacterium bifidum, biological therapy, CD4+ T lymphocyte, cell therapy, chimeric antigen receptor immunotherapy, chronic inflammation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29021
International Journal of Molecular Sciences
LibKey Link